Express News | Myriad Genetics Inc - Continues Development of Precise Mrd Assay
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) With Early Priority Date
Express News | Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (Mrd) With Early Priority Date
Wells Fargo Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $35
Myriad Genetics Has Many Opportunities for Growth, Needs Sustained Execution, Morgan Stanley Says
Analyst Expectations For Myriad Genetics's Future
Myriad Genetics Price Target Announced at $32.00/Share by Morgan Stanley
Myriad Genetics Analyst Ratings
Myriad Venture Partners Announces Executive Advisory Board
Morgan Stanley Initiates Myriad Genetics(MYGN.US) With Hold Rating, Announces Target Price $32
Morgan Stanley analyst Tejas Savant initiates coverage on $Myriad Genetics(MYGN.US)$ with a hold rating, and sets the target price at $32.According to TipRanks data, the analyst has a success rate
Morgan Stanley Initiates Myriad Genetics at Equalweight
Myriad Genetics: A Balanced Outlook Amidst Growth and Market Challenges
Here's Why Myriad Genetics (MYGN) Is a Strong Momentum Stock
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
Myriad Genetics to Host Investor Event on October 9, 2024
Myriad Genetics Insider Sold Shares Worth $1,285,851, According to a Recent SEC Filing
Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN)
Sector Update: Health Care Stocks Softer Late Afternoon